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Background: Treatment of locally advanced non-small-cell lung cancer is based on a combined approach. To study
the impact of trimodal therapy for stage III-N2 NSCLC a single centre retrospective evaluation focusing on survival
and therapy-related toxicity was performed.
Methods: 71 patients diagnosed between March 2001 and August 2008 with pathologically confirmed stage III-N2
non-small-cell lung cancer at the University Clinic of Heidelberg were retrospectively analyzed. All patients were
treated within trimodal therapy strategies including surgery, induction or adjuvant chemotherapy and postoperative
radiotherapy. Overall survival (OS) and disease free survival (DFS) rates were calculated using the Kaplan-Meier
method. The log-rank test and Fishers Exact test were applied for univariate analysis and Cox proportional
regression model for multivariate analysis.
Results: Median survival was 32 months. 1-, 3- and 5-year overall survival (OS) rates were 84.5%, 49.6% and 35.5%
respectively. Disease free survival rates at 1, 3 and 5 years were 70.4%, 41.8% and 27.4% respectively. 9 patients
(12.6%) were diagnosed with a local recurrence. Multivariate analysis did not reveal any independent prognostic
factors for OS, but indicated a trend for pT stage and type of surgery. In regard to toxicity 8.4% of the patients
developed a clinically relevant≥ grade 2 pneumonitis. Evaluation of the forced expiratory volume in 1 second per
unit of vital capacity (FEV1/VC) before and 1-3 years post radiotherapy revealed a median decrease of 2.1%.
Conclusions: Our descriptive data indicate that trimodal therapy represents an effective and safe treatment
approach for patients with stage III-N2 non-small-cell lung cancer. Further prospective clinical trials are necessary in
order to clearly define the impact of multimodal strategies and optimize NSCLC treatment.
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Lung cancer is the leading cause of cancer mortality in
industrialized nations. The disease is diagnosed worldwide
in about 1.35 million patients and is responsible for about
1.18 million deaths yearly [1]. Non-small-cell lung cancer
(NSCLC) accounts for about 80% of all cases, whereas
one-third of the patients are diagnosed with stage III
disease, characterized in most cases by involvement of
mediastinal lymph nodes (N2). Clinical trials have* Correspondence: v.askoxylakis@gmail.com
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article, unless otherwise stated.investigated various therapeutic methods, based on both
mono- and multimodal approaches. Surgical resection has
a key role for resectable cases, however the prognosis
is poor when it is not combined with further modalities.
This is mainly attributed to the fact that stage III
non-small-cell lung cancer is associated with a high
probability for local and distant failure, supporting the
thesis that at this stage NSCLC has potentially features of
a systemic disease [2]. Furthermore, the complexity of
treating stage III NSCLC is strengthened by the high
heterogeneity in the patient collective [3].
The poor treatment outcome for stage III NSCLC
indicates the necessity for the development of neoadjuvanttral Ltd. This is an Open Access article distributed under the terms of the
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past decade to numerous clinical trials investigating the
efficacy of multimodal approaches. Such approaches
focussed mainly on two subsets of patients. The first subset
included patients with low tumor burden, considered to be
resectable at diagnosis, whereas the second subset
consisted of patients with locally advanced tumors
that were not considered resectable at diagnosis. In both
cases the rationale for the multimodal approaches is based
on the optimization of distant disease control through
chemotherapy at the possible lowest micrometastatic
burden and the optimization of the locoregional control
through radiation therapy [4,5].
The high impact of chemotherapy on treatment
outcome has been demonstrated by several trials leading
to the establishment of systemic treatment as standard
therapy besides surgery. In particular, survival was found to
be improved when pre-operative induction chemotherapy
was applied to patients with resectable disease compared
to surgery alone [6,7]. Furthermore, a pooled analysis of 5
randomized studies including more than 4,500 patients
revealed a 17% reduction in the risk of death for stage III
patients receiving cisplatin-based adjuvant chemotherapy
[8]. Among prospective phase III trials the Adjuvant
Navelbine International Trialist Association (ANITA) study
investigated the effects of postoperative chemotherapy in
patients with completely resected NSCLC stage IB-IIIA
revealing a 5-year overall survival improvement of 8.6%,
with a subset analysis demonstrating the highest survival
profit for those with stage IIIA disease [9].
However, although the role of chemotherapy has been
extensively characterized, there is still an increased need
to evaluate the impact of radiotherapy in multimodal
treatment settings of stage III NSCLC. A randomized
phase III trial investigating concurrent radiotherapy and
chemotherapy followed by surgery versus chemotherapy
with definitive radiotherapy without surgery, showed a
statistically improved progression free survival for the
trimodal therapy concept, as well as a trend to improved
5-year overall survival [4]. A further phase III trial
investigated the effects of preoperative chemo-radiation in
addition to preoperative chemotherapy for patients with
NSCLC stage III, revealing an improvement in pathological
response and mediastinal downstaging but also an
increased post-pneumonectomy mortality [10]. In regard
to adjuvant radiotherapy a retrospective analysis of data
generated by the ANITA trial revealed an improved 5-year
survival for patients with pN2 status who received
additional postoperative radiotherapy both in the
chemotherapy and the observation arm [11]. However,
a large meta-analysis in the past did not reveal the
same benefit. The PORT meta-analysis did not show
a significant survival benefit for stage III/N2 patients,
allowing the conclusion that the role of postoperativeradiotherapy in the treatment of N2 tumors is not
clear and needs further research [12]. More recent
meta-analysis support the hypothesis that modern
postoperative radiotherapy may improve local control
and survival [13], still further evidence is necessary.
Therefore, aim of the current study is to evaluate the
results of a retrospective analysis of 71 patients with
stage III-N2 NSCLC, who received trimodal treatment
in our institution, including postoperative radiation
therapy. The main hypothesis is that trimodal treatment is
effective, with acceptable toxicity. Beside overall and
disease free survival a subset analysis of treatment
outcome and toxicity has been performed in order to
generate information that will form the basis for further
prospective trials focusing on the role of multimodal




71 patients diagnosed between March 2001 and August
2008 with pathologically confirmed stage III-N2 non-
small-cell lung cancer and treated within a trimodal
approach at the University Hospital of Heidelberg
were included in our analysis. N2 status was histologically
confirmed in all cases (pN2). Preoperative staging
included for all patients CT-scans of the thorax,
abdomen and brain, as well as a bone scan. Retrospective
evaluation of the patients´ medical records and follow-up
data was performed. Analysis included gender, age,
histology, tumor site, TNM classification, tumor resection,
R-status, chemotherapy, radiotherapy, patterns of
treatment failure, disease free survival, overall survival
and radiation induced toxicity.
Surgery
All patients underwent lobectomy, bilobectomy or
pneumonectomy. Surgical treatment included a systematic
multilevel mediastinal lymph node dissection. Among 44
patients who received lobectomy, 4 (9%) received a sleeve
resection.
Chemotherapy
70 patients received platin-based chemotherapy. Among
them 43 received cisplatin-based and 27 carboplatin-based
chemotherapy. 1 Patient received gemcitabine monother-
apy. 23 patients received preoperative induction chemo-
therapy with a median of three cycles (range 1-3). 48
patients received postoperative chemotherapy with a
median of four cycles (2-4). The decision for neoadjuvant
versus adjuvant chemotherapy was an individual decision,
based on tumor characteristics, such as tumor size or
resectability at diagnosis. The chemotherapy choice
(cisplatin versus non-cisplatin) was based on the
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function.Radiotherapy
All patients received postoperative radiotherapy (PORT).
PORT was applied as three-dimensional conformal radio-
therapy (3DCRT). The target volume included mediastinal
nodes. Patients with R0 resection received a median dose
of 50 Gy (range 50-56 Gy), whereas patients with R1
status received a boost of 10 Gy to a total median
dose of 60 Gy (range 40-60 Gy). Patients with primary
tumor localization in the upper lobe or involvement of
upper mediastinal lymph nodes received individually an
irradiation of the supraclavicular fossae to a median total
dosis of 50 Gy. Radiation therapy was performed with a
linear accelerator at 2 Gy per fraction, 5 days per week.Follow up
Patient follow up was performed at 6-8 weeks post radiation
treatment and then every 3 months for the first 2 years and
thereafter every 6 months. Follow-up included a physical
examination and thoracic computed tomography scans, as
well as further imaging modalities dependent on the
patient´s clinical symptoms. All patients received function
tests, including forced expiratory volume in 1 s (FEV1) and
vital capacity (VC) post surgery but pre-radiotherapy. In 31
cases (44%) post treatment pulmonary function tests were
performed at 1-3 years after radiation treatment. Data
cut-off was defined as the date of the last follow-up visit at
the University Hospital of Heidelberg. Thereafter, only
data on survival was obtained by the patient’s physician of
choice.Data analysis
Overall survival (OS) was defined from the day of treatment
begin to the time of death from any cause or last follow up.
Disease free survival (DFS) was defined from the day
of treatment begin to the day of disease local or distant
recurrence, diagnosed by imaging examinations according
to the RECIST criteria (Response Evaluation Criteria in
Solid Tumours) [14], death or last follow up. Pneumonitis
was defined by clinical as well as radiographic findings
correlating to the irradiated lung volumes. Pneumonitis
was considered clinically relevant (≥grade 2 according to
RTOG scale) if persistent cough required antitussive
agents or administration of steroids and hospitalization.
The ratios of FEV1 and VC at 1-3 years post radiotherapy
to the respective values before radiotherapy but post
surgery were calculated for assessment of radiation induced
changes in the pulmonary function. The forced expiratory
volume in 1 s per unit of vital capacity (FEV1/VC) was
assessed and used as a measure for obstruction.Statistics
Statistical analysis was performed using the Statistica
version 6.1 Software (StaSoft Inc®, Tulsa OK, USA) and
the STATA 13 Data Analysis and Statistical Software.
Survival rates were calculated using the Kaplan-Meier
method. Subgroup analysis was performed using the
log-rank test and Fishers Exact test. Multivariate analysis
was performed using a Cox proportional hazards regres-
sion model. A p value <0.05 was considered statistically
significant.
Ethics
The study was approved by the ethics committee of




Median patient age was 59 years (range, 29-75 years).
Median follow-up was 30 months (range, 6-93 months).
Histology analysis revealed that 25 patients had a squamous
cell carcinoma (35.2%) and 41 adenocarcinoma (57.7%).
The mean number of dissected lymph nodes was 33
(range, 10-60). All patients received postoperative
radiotherapy with a mean dose of 50 Gy for R0 resection
(range, 50-56 Gy) and a mean dose of 60 Gy for R1
resection (range, 40-60 Gy). The median interval between
surgery and postoperative radiotherapy was 1 month
(range, 1-3 months) for the group of patients receiving
preoperative chemotherapy and 4 months (range 2-12
months) for the group of patients receiving postoperative
chemotherapy. Patients´ characteristics are presented
in Table 1.
Survival results
Overall analysis revealed a median survival time of
32 months. 1-, 3- and 5-year survival rates were 84.5%,
49.6% and 35.5% respectively. Disease-free survival rates
at 1, 3 and 5 years were 70.4%, 41.8% and 27.4%. The
Kaplan-Meier estimates for OS and DFS are presented
in Figure 1 and Figure 2 respectively.
Investigation of differences in OS and DFS between
various groups was performed using the log-rank test and
the Fishers Exact test. Univariate analysis is presented
in Table 2. For patients with R0 and R1 resection, the
median survival time was 33 and 31 months respectively.
The 1-, 3- and 5-year OS rates were 82.6%, 49.4% and
37.6% for the R0 group and 80%, 51.4% and 43.5% for the
R1 group (p = 0.54). The respective values for 1-, 3- and
5-year DFS were 67.4%, 37.0% and 32.3% for R0 and
73.3%, 51.6% and 22.1% for R1 resection. A local relapse
was noticed in 5 patients from the R0 group (9.4%) and 4
patients from the R1 group (22.2%).
Table 1 Patients characteristics
Clinical characteristics Number (n) %
Total number 71 100
Age (years)
Median 59















Right upper lobe 28 39
Right middle lobe/central 5 7
Right lower lobe 9 13
Left upper lobe 16 23
Left lower lobe 13 18
Tumor histology
Squamous cell 25 35
Adenocarcinoma 41 58
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patients with squamous cell carcinoma (SCC) and
adenocarcinoma. Median survival was 43 months for
SCC but only 21 months for adenocarcinoma. 1-, 3- and
5-years OS and DFS for SCC were 85%, 60% and
42.5%, and 80.0%, 55.0% and 34.2% respectively. For
adenocarcinoma OS and DFS were 77.1%, 42.0%, 36.0%
and 60.0%, 28.6% and 28.6% respectively (p = 0.20 for OS
and p = 0.21 for DFS).
In regard to chemotherapy, analysis focused on the
time of chemotherapy in respect to surgery (induction
vs. postoperative chemotherapy). The group of patients
that received induction chemotherapy had a median
survival of 36 months. 1-, 3- and 5-year OS was 81.8%,
53.3% and 38.7%, whereas the respective DFS values
were 68.2%, 45.5% and 31.8%. Patients who received
postoperative chemotherapy showed similar results
(82.0%, 48.1% and 38.7% OS rates and 69.2%, 37.8%
and 28.7% DFS rates at 1, 3 and 5 years respectively).
The median survival was 32 months for adjuvant
chemotherapy. No significant difference was noticed
(p = 0.87 for OS and p = 0.79 for PFS).
Patients who received cisplatin had a median survival of
41 months. In comparison median survival was 22 months
for patients who did not receive cisplatin. 1-, 3- and 5-year
OS was 83.8%, 54.1% and 40.2% for cisplatin-containing
treatment and 79.2%, 43.5% and 36.8% for non-cisplatin
chemotherapy.
To evaluate the role of surgical treatment for therapy
outcome, overall survival was analyzed for the group of
patients who received lobectomy and the group of patients
who received bilobectomy or pneumonectomy. Median
survival was 43 months for the lobectomy group and
22 months for the bilobectomy/pneumonectomy group.
1-, 3- and 5-years overall survival was 86.0%, 59.5%
and 51.9% for the lobectomy group and 78.6%, 35.7% and
19.5% for the bilobectomy/pneumonectomy group respect-
ively. Log rank analysis revealed that this difference just
failed statistical significance (p = 0.054).
The multivariate analysis using a Cox regression model
did not reveal any statistically significant independent prog-
nostic factors for overall survival (Table 3), but indicated a
trend for pT stage (HR = 1.71, 95% CI: 0.92-3.18, p = 0.088)
and the type of surgery (bilobectomy/pneumonectomy
versus lobectomy, HR = 2.01, 95% CI: 0.92-4.39, p = 0.078).
Distant metastasis
Among 71 patients initially diagnosed with stage III
NSCLC, 31 patients (44%) developed distant metastases,
8 patients (11.2%) pulmonary metastases, whereas 7 patients
(9.8%) developed bone metastases. The majority of the cases
with distant failure (16 patients, 22.5%) were diagnosed
with cerebral metastases. The median distant metastasis
free survival was 13 months (range, 2-33 months). Among
Figure 1 Overall survival.
Askoxylakis et al. BMC Cancer 2014, 14:572 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/572all patients with distant metastases 22 patients (71%) were
diagnosed with adenocarcinoma, whereas only 9 patients
(29%) had a non-adenocarcinoma disease (p = 0.039).
The respective values for cerebral metastases were
81% (13 cases) for adenocarcinoma and 19% (3 cases)
for non-adenocarcinoma histology (p = 0.028).Figure 2 Disease free survival.Radiation toxicity
Toxicity of postoperative radiotherapy within the trimodal
treatment of patients with stage III non-small-cell lung
cancer was investigated. Among 71 patients that were
included in the analysis 6 (8.4%) developed a clinically
relevant ≥ grade 2 pneumonitis. All cases developed
Table 2 Treatment outcome after trimodal therapy




R0 33 37.6 0.54
R1 31 43.5
Histology
Squamous cell 43 42.5 0.20
Adenocarcinoma 21 36.0
Chemotherapy
Induction 36 38.7 0.87
Adjuvant 32 38.7
Type of surgery
Lobectomy 43 51.9 0.054
Bi-lobe/Pneumonectomy 22 19.5
Univariate analysis.
Askoxylakis et al. BMC Cancer 2014, 14:572 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/572within 120 days post radiation treatment. 4 patients
(5.6%) developed a grade 3 esophagitis, whereas in 1 case
(1.4%) an esophago- tracheal fistula was diagnosed. To
evaluate the functional effects of mediastinal radiotherapy,
pulmonary function post-surgery but pre-radiotherapy
was investigated and compared to the pulmonary function
1-3 years post-radiotherapy. The post-to-pre radiotherapy
ratio of FEV1 was 89%, whereas the same value for VC
was calculated to be about 92% (Figure 3). Evaluation of
the forced expiratory volume in 1 s per unit of vital
capacity (FEV1/VC) revealed a median decrease post
radiotherapy of 2.1%.
Discussion
The optimal treatment for stage III non-small cell lung
cancer is subject of intensive clinical research, mainly
due to the fact that this stage includes patients with
heterogeneous disease characteristics. Aim of the
present study is to evaluate the impact of trimodal
treatment in patients with stage III-N2 NSCLC. We
performed a retrospective analysis of 71 cases that received
surgical resection including mediastinal lympadenectomy,
induction or adjuvant chemotherapy and postoperative
radiation treatment. The 5-year overall and progression







Non-cisplatin 1.3349 .55323failure after radiotherapy was 12.6%. Statistical compari-
sons between various groups revealed a trend for
improved outcome for patients with non-adenocarcinoma
histology, patients that received cisplatin-based chemo-
therapy and patients who underwent simple lobectomy.
Toxicity analysis demonstrated > grade 2 pneumonitis and
oesophagitis rates of 8.4% and 5.6% respectively and
revealed that postoperative radiotherapy caused a 10%
decrease of FEV1 and VC. Our study furthermore showed
that 44% of the patients developed distant metastases with
the majority diagnosed with cerebral metastatic disease.
Analyses of the outcome of multimodal combinatorial
treatments for stage III NSCLC are of high clinical
significance and relevance. Whereas the role of
chemotherapy in the treatment of stage III NSCLC has
been extensively investigated, the impact of postoperative
radiation therapy within multimodal approaches has not
been completely cleared. Based on the fact that resected
stage III-N2 patients have locoregional relapse rates
varying between 18% with and 29% without chemotherapy
[11] the role of postoperative radiotherapy seems to
be crucial. Although data clearly indicate a significant
reduction in local recurrence after postoperative radio-
therapy for N2 NSCLC, the survival effects remain
controversial [15-17].
Our study revealed a median OS of 32 months and a
5-year OS rate of 35.5% for the trimodal treatment,
which seems to be higher compared to the survival rates
of the SEER analysis (27% 5-year OS) [15]. However, the
SEER database evaluation did not include data on the use
of chemotherapy, which impedes a comparison to our data.
On the contrary in comparison to the results of the
ANITA trial our results seem on a first view to be inferior.
In particular, within the ANITA trial patients with N2
disease who received a postoperative radiation therapy had
a median survival of 47.4 months and a 5-year survival of
47.4% in the chemotherapy group [9]. The discrepancy
between the ANITA trial and our study is minimized when
the chemotherapy scheme is included in the analysis.
Considering that patients in ANITA received cisplatin-
based chemotherapy, analysis of our data showed that the
cisplatin-based chemotherapy group had improved survival
(median 41 months, 5-year OS rate 40.2%), which was
comparable to the outcome of the ANITA trial.z P > |z| [95% conf. interval]
-0.27 0.790 .9588233 1.032488
1.70 0.088 .9225897 3.181654
-1.14 0.256 .2622703 1.427124
1.76 0.078 .9238394 4.390594
1.09 0.277 .6972494 3.523288
0.70 0.486 .5925367 3.007608
Figure 3 Post- to pre-radiotherapy ratio FEV1 and VC. Mean values and standard deviation.
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NSCLC involve trials of preoperative radiochemotherapy.
Prominent examples of phase III randomized controlled
trials are the INT 0139/RTOG 9309 [4] and the German
Cancer Cooperative Group study [10]. Within the INT
0139 study 216 patients with N2-lymph node status
received induction chemotherapy plus radiotherapy to
a dose of 45 Gy followed by surgery. Median survival and
5-year survival were 23.6 months and 27% respectively.
Our retrospective data indicate improved survival, which
might be attributed to the fact that in the INT0139 study
patients received preoperative radiation treatment. A
negative impact of preoperative radiation therapy has been
revealed in the GLCCG trial. Thomas et al. showed
that treatment related mortality was increased when
radiotherapy was applied prior to surgery, an effect that
was stronger for the group of patients who received
pneumonectomy [10]. Lower 5-year survival rates
were reported in more recent trials of a trimodality
regimen with neoadjuvant radiochemotherapy (21.7%),
however the majority of the patients in the study by
Friedel et al. had stage IIIB disease [18]. A multicentric
phase II trial by Stupp et al. revealed a median overall
survival of 29 months and 5-year survival rate of 40% for
patients with stage IIIB NSCLC who received neoadjuvant
chemotherapy and radiotherapy followed by surgery [19].
In addition, recently the phase II trial CISTAXOL
reported 10-year long-term survival of 26% [20]. These
data indicate that despite the fact that definitive radioche-
motherapy is preferred for stage IIIB disease [21], trimodal
treatment including surgery should be considered for
cases that are technically resectable.
In regard to the role of postoperative radiotherapy on
locoregional control our data revealed a local relapserate of 12.6% for the entire patient cohort and 9.4% for
patients after R0 resection. These rates are higher
compared to the results of a retrospective analysis of
the ANITA trial, which revealed locoregional relapse
in 6.3% of the patients with pN2 who were randomized to
chemotherapy and received postoperative radiotherapy.
However the local relapse rates for the entire population
in the ANITA trial were 12% in the chemotherapy group
and 18% in the observation group [9]. Considering that
the ANITA trial included also patients with lower disease
stages (IB-IIIA) and that about 22% of the patients in
the chemotherapy arm received additional postoperative
radiotherapy higher local relapse rates are expected for
stage IIIA patients without radiation treatment. This is also
supported by data from studies in which patients received
only chemotherapy and surgery. In particular chemother-
apy followed only by surgery revealed local failure rates of
about 23.6-29% [22,23]. Despite limitations, a comparison
of our data to these results indicates a superior local control
for the trimodal treatment.
No survival difference between induction and postopera-
tive chemotherapy was shown in our analysis. This result
seems to be in concert with meta-analyses indicating
an absolute 5-year survival benefit of about 5% for
neoadjuvant chemotherapy [24,25]. Despite limitations
in comparing the data of meta-analyses on pre- and
postoperative chemotherapy, the benefit of preoperative
chemotherapy seems to be similar to the benefit of adjuvant
approaches, allowing the suggestion that the relative
effects of neoadjuvant and adjuvant systemic therapy are
comparable. However, data indicate a higher compliance
for preoperative chemotherapy (about 90%), compared to
postoperative treatment (about 60%) [25,26]. Although
safe conclusions are limited by the fact that such data are
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still, they reveal that determination of the optimal therapy
sequence is of high importance and needs to be further
evaluated in prospective, randomized, clinical trials apply-
ing multimodal treatment. In addition to the therapy
sequence, we further investigated whether cisplatin-based
chemotherapy was associated with improved therapy
outcome. Indeed, median survival was 41 months for
cisplatin-based and 22 months for non-cisplatin-based
chemotherapy, whereas 5-year survival rates were
40.2% and 36.8% respectively. This trend for improved
outcome seems to be in concert with previous meta-
analyses indicating a survival advantage for cisplatin-based
adjuvant treatment [27]. More recent analyses of clinical
trials in patients with advanced NSCLC show higher
response rates for cisplatin in combination with third
generation drugs, but not a benefit in overall survival [28].
Therefore, the trend for improved survival for cisplatin-
based regimens must be interpreted with great caution,
mainly because patients that receive cisplatin-based
chemotherapy are characterized by better performance
status and less comorbidities, which facilitates selection
bias of the results.
Interestingly, patients with adenocarcinoma showed in
our study a trend to poorer outcome, compared to
patients with SCC. Although adenocarcinoma is known
to be a potentially poor prognostic factor in patients
with resected NSCLC, the addition of chemotherapy
revealed in previous studies an increased benefit for this
histological subtype, allowing the hypothesis that this
parameter may be a predictive factor for enhanced multi-
modal treatment benefit [29]. A possible explanation for
the survival difference in our analysis might be the signifi-
cant difference in distant failure rates between the group of
patients with adenocarcinoma and non-adenocarcinoma
histology. Especially in regard to cerebral metastases, previ-
ous studies have confirmed the correlation between brain
progression and histological features [30,31], raising again
the question of a possible benefit through prophylactic cra-
nial irradiation (PCI). A recent study reassessing the poten-
tial of PCI in the current era of multimodal NSCLC
treatment, demonstrated that PCI decreases the rate of
brain metastases but does not seem to improve overall sur-
vival [32]. Although PCI is not recommended as standard
therapy in NSCLC on the basis of this data, still further
studies focusing on high risk patients, including adenocar-
cinoma need to be performed. In this direction a new
multidisciplinary classification of adenocarcinomas, based
on pathologic, molecular and radiologic features is expected
to facilitate the improvement of patient stratification [33].
Both univariate and multivariate analysis indicated that
the type of surgery might have an influence on treatment
outcome. In particular, bi-lobectomy/pneumonectomy
was associated with a strong trend to a decreased survivalcompared to lobectomy. This result is in concert with
further studies showing that lobectomy was marginally
associated with a higher overall survival rate compared to
pneumonectomy [34] and can be logically explained by
the fact that patients who are stratified to bilobectomy or
pneumonectomy have usually tumors with disadvanta-
geous characteristics, such as larger size and/or infiltration
of central structures. Similar to previous analyses the type
of surgery was not found in our analysis to be of prognos-
tic significance. Considering however the fact that the
p value was very close to the significant level (p < 0.05),
this might be attributed to the relative low number of
patients included in our study. Therefore, further
investigation is necessary in order to generate safe
conclusions. However, when lobectomy/bi-lobectomy was
compared to pneumonectomy there was no significant
difference (p = 0.3), a result which is in concert with
further recent studies, indicating that pneumonectomy
can be done safe and may not be a risk factor for survival
in trimodal therapy of stage III NSCLC [35].
A major drawback in the use of multimodal therapeutic
approaches for NSCLC is the treatment-related toxicity.
In this respect post-operative radiotherapy is mostly
associated with pneumonitis. A study focusing on
radiation-induced lung injury for postoperative radiother-
apy and the impact of pre-radiotherapy surgery on it
revealed a symptomatic pneumonitis rate of about 19%,
which was similar in surgical and non-surgical groups
[36]. Further analyses revealed that pneumonitis occurs in
1-28% of lung cancer patients treated with postoperative
radiotherapy [37], with the irradiated volume of healthy
lung parenchyma known to be the most important risk
factor. However the results between the various trials
cannot be directly compared due to a large hetero-
geneity in the patient collectives. In our analysis clinically
relevant > grade 2 pneumonitis was noticed in 8.4% of all
cases. This might be associated with the fact that only low
volumes of lung parenchyma were irradiated since target
definition included in most cases only the mediastinal
lymphatics. However, a recent phase II trial on neoadju-
vant chemoradiation for stage III NSCLC revealed com-
parable results (8.5% grade 2 pneumonitis) [38]. A further
issue associated with radiation toxicity in NSCLC refers to
alterations in pulmonary function, which is mostly
observed as a decrease in diffusion capacity and FEV1.
Whereas older studies have shown an FEV1 decrease of
about 10-20% [39], our analysis demonstrated a decrease
of about 11% for FEV1 after adjuvant radiotherapy within
multimodal approaches. Furthermore, a decrease in the
ratio FEV1/VC of about 2.1% was calculated in our study.
In comparison, a recent analysis of 250 patients who had
received ≥60 Gy radiotherapy for primary NSCLC showed
a decrease in the median FEV1/VC level after radiother-
apy of 3.7% 9-12 months post treatment [40]. It should be
Askoxylakis et al. BMC Cancer 2014, 14:572 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/572mentioned, however, that the lung function might be
influenced by the time interval between surgery and
radiotherapy, considering that thoracic surgery can result
in both a permanent decrease of lung function due to
resection of pulmonary parenchyma, and a temporary
reduction due to reversible tissue changes on the remaining
parenchyma. Since there are different medians in the time
between surgery and postoperative radiotherapy for
the neoadjuvant and the adjuvant setting, we performed
the analyses for the 2 settings separately. For patients
receiving adjuvant chemotherapy (median time between
surgery and RT 4 months) the post-to-pre radiotherapy
ratio of FEV1 was 90%, whereas the same value for VC
was 92%. For the group of patients receiving neoadjuvant
chemotherapy (median time between surgery and RT
1 month) the respective values were 87% and 91%.
Despite the differences in the time between surgery
and radiotherapy between the 2 groups the differences
in%FEV1 and VC were not statistically significant in our
study. Still, the intervall between resection and radiother-
apy is very important and should be critically considered
in further analyses, focussing on the pulmonary function
after multimodal therapeutic approaches.Conclusions
In conclusion, the present descriptive data indicate that
trimodal combinatorial therapy represents an effective
and safe treatment approach for patients with resectable
stage III-N2 non-small-cell lung cancer. Addition of post-
operative radiotherapy to the established combination
of surgery and chemotherapy facilitates the improvement
of locoregional control. Although our results are mostly in
concert with previous trials and further related stud-
ies, critical limitations need to be considered. Beside
the retrospective character of our work, which might
facilitate selection bias, the included number of patients
might not allow safe statistical conclusions, emphasizing
the necessity for cautious interpretations. Therefore,
further analyses of larger patient collectives as well as
prospective clinical trials are necessary in order to
clearly define the impact of postoperative radiotherapy
within multimodal therapeutic strategies for stage III
disease, identify patients with improved benefit/risk
ratios and optimize treatment of non-small-cell lung
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